

# Roberto Labianca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1028899/publications.pdf>

Version: 2024-02-01

243  
papers

26,321  
citations

10956

71  
h-index

6282

158  
g-index

251  
all docs

251  
docs citations

251  
times ranked

23550  
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. <i>TH Open</i> , 2021, 05, e56-e65.	0.7	9
2	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 631-641.	0.8	63
3	Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. <i>European Journal of Cancer</i> , 2021, 148, 190-201.	1.3	4
4	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td <i>Lancet Oncology</i> , The, 2020, 21, 1620-1629.	5.1	152
5	Thrombin generation predicts early recurrence in breast cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2220-2231.	1.9	17
6	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	1.3	15
7	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. <i>Haematologica</i> , 2020, 105, 1704-1711.	1.7	21
8	Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. <i>Oncologist</i> , 2020, 25, e928-e935.	1.9	8
9	Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. <i>Scientific Reports</i> , 2019, 9, 11527.	1.6	13
10	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	5.1	51
11	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1177-1188.	13.9	699
12	FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1478-1485.	0.8	59
13	Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. <i>European Journal of Cancer</i> , 2017, 81, 174-182.	1.3	12
14	Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. <i>Thrombosis Research</i> , 2016, 140, S55-S59.	0.8	29
15	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. <i>Journal of Geriatric Oncology</i> , 2016, 7, 422-429.	0.5	9
16	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 1182-1189.	0.8	32
17	A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. <i>Annals of Oncology</i> , 2016, 27, 274-280.	0.6	111
18	Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). <i>Scientific Reports</i> , 2015, 5, 16331.	1.6	10

#	ARTICLE	IF	CITATIONS
19	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. <i>Oncotarget</i> , 2015, 6, 35087-35094.	0.8	40
20	FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. <i>Clinical Colorectal Cancer</i> , 2015, 14, 162-169.	1.0	11
21	Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research. <i>Journal of Medical Ethics</i> , 2015, 41, 799-803.	1.0	6
22	Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. <i>Scientific Reports</i> , 2015, 4, 6828.	1.6	31
23	Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population. <i>Annals of Oncology</i> , 2015, 26, 950-958.	0.6	11
24	Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial. <i>Oncology</i> , 2015, 88, 273-280.	0.9	24
25	Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. <i>Annals of Oncology</i> , 2015, 26, 2079-2084.	0.6	42
26	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015, 28, 1481-1491.	2.9	226
27	Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. <i>Pancreatology</i> , 2015, 15, 8-18.	0.5	404
28	MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 1077-1086.	1.9	68
29	A prospective study on survival in cancer patients with and without venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2014, 9, 559-67.	1.0	27
30	Tivantinib: critical review with a focus on hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1563-1574.	1.9	18
31	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Annals of Oncology</i> , 2014, 25, 1373-1378.	0.6	84
32	Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon- $\gamma$ (IFN- $\gamma$ ) in Operable Renal Cell Carcinoma (RCC). <i>Journal of Immunotherapy</i> , 2014, 37, 440-447.	1.2	61
33	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	62
34	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. <i>Digestive and Liver Disease</i> , 2014, 46, 182-186.	0.4	40
35	Communication Models for Doctor-Patient Relationships. <i>Journal of Cancer Education</i> , 2014, 29, 211-212.	0.6	7
36	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). <i>European Journal of Cancer</i> , 2014, 50, 2983-2993.	1.3	56

#	ARTICLE	IF	CITATIONS
37	"Green Oncology": the Italian medical oncologists' challenge to reduce the ecological impact of their clinical activity. <i>Tumori</i> , 2014, 100, e94-7.	0.6	3
38	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. <i>Lancet Oncology</i> , The, 2013, 14, 981-988.	5.1	472
39	Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 12-27.	2.0	19
40	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 261-269.	1.0	94
41	Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. <i>Cancer</i> , 2013, 119, 1528-1536.	2.0	141
42	Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSDY). <i>European Urology</i> , 2013, 63, 254-261.	0.9	29
43	Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi64-vi72.	0.6	874
44	Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. <i>Annals of Oncology</i> , 2013, 24, 406-411.	0.6	126
45	Appropriateness and Right Price: An Inseparable Binomial to Improve Care and Reduce Cost. <i>Journal of Clinical Oncology</i> , 2013, 31, 2223-2223.	0.8	1
46	A randomized phase II non-comparative study of pemetrexed-carboplatin and gemcitabine-vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients. <i>International Journal of Oncology</i> , 2013, 42, 1778-1785.	1.4	11
47	The MaiSON Project (Italy). Developing integration strategies for oncology organizations/associations through a participatory approach. <i>Tumori</i> , 2013, 99, 122-4.	0.6	0
48	Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set. <i>Journal of Clinical Oncology</i> , 2012, 30, 2334-2339.	0.8	34
49	Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies. <i>British Journal of Cancer</i> , 2012, 107, 612-616.	2.9	4
50	Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). <i>British Journal of Cancer</i> , 2012, 106, 658-665.	2.9	18
51	Tackling Off-Label Use of Anticancer Drugs. <i>Journal of Clinical Oncology</i> , 2012, 30, 2800-2800.	0.8	3
52	Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 4501-4507.	0.8	47
53	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. <i>Annals of Oncology</i> , 2012, 23, 2479-2516.	0.6	1,233
54	Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1635-1646.	3.0	227

#	ARTICLE	IF	CITATIONS
55	Barriers to Pain Management. <i>Clinical Drug Investigation</i> , 2012, 32, 11-19.	1.1	53
56	The Appropriate Treatment of Chronic Pain. <i>Clinical Drug Investigation</i> , 2012, 32, 21-33.	1.1	70
57	Adverse Effects Associated with Non-opioid and Opioid Treatment in Patients with Chronic Pain. <i>Clinical Drug Investigation</i> , 2012, 32, 53-63.	1.1	149
58	The Management of Chronic Pain in Important Patient Subgroups. <i>Clinical Drug Investigation</i> , 2012, 32, 35-44.	1.1	33
59	A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. <i>Internal and Emergency Medicine</i> , 2012, 7, 291-292.	1.0	299
60	FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1641-1645.	1.1	78
61	Episodic (Breakthrough) Pain Prevalence in a Population of Cancer Pain Patients. Comparison of Clinical Diagnoses With the QUIDE™ Italian Questionnaire for Intense Episodic Pain. <i>Journal of Pain and Symptom Management</i> , 2012, 43, 833-841.	0.6	62
62	DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2011, 103, 863-875.	3.0	469
63	Association of Socioeconomic Status With Breslow Thickness and Disease-Free and Overall Survival in Stage I-II Primary Cutaneous Melanoma. <i>Mayo Clinic Proceedings</i> , 2011, 86, 113-119.	1.4	28
64	Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. <i>British Journal of Cancer</i> , 2011, 104, 1786-1790.	2.9	65
65	Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 37-43.	1.1	15
66	Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. <i>Journal of Translational Medicine</i> , 2011, 9, 179.	1.8	90
67	Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non-Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2011, 12, 138-141.	1.1	15
68	Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised GISCAD™ trial. <i>Annals of Oncology</i> , 2011, 22, 1236-1242.	0.6	98
69	Large-Cell Neuroendocrine Carcinoma of the Lung Harboring EGFR Mutation and Responding to Gefitinib. <i>Journal of Clinical Oncology</i> , 2011, 29, e819-e822.	0.8	70
70	Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon- $\gamma$ for metastatic renal cell cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 553-561.	2.0	22
71	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 106-133.	2.0	285
72	Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1645-1651.	0.8	279

#	ARTICLE	IF	CITATIONS
73	Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. <i>Annals of Oncology</i> , 2010, 21, 871-876.	0.6	76
74	Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control Study. <i>Nephron Clinical Practice</i> , 2010, 115, c154-c160.	2.3	79
75	Video meliora proboque sed deteriora sequor: the case of thromboprophylaxis in hospitalized cancer patients. <i>Annals of Oncology</i> , 2010, 21, 911-913.	0.6	2
76	Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v70-v77.	0.6	275
77	Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3219-3226.	0.8	1,352
78	Prevention and treatment of pandemic influenza in cancer patients. <i>Annals of Oncology</i> , 2010, 21, 2301-2303.	0.6	8
79	Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). <i>Digestive and Liver Disease</i> , 2010, 42, 831-838.	0.4	31
80	Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 466-474.	0.8	1,048
81	Venous thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management. <i>Thrombosis Research</i> , 2010, 125, S117-S119.	0.8	39
82	Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey. <i>Tumori</i> , 2009, 95, 647-651.	0.6	18
83	Prospective, Multicenter, Randomized Trial of a New Organizational Modality for Providing Information and Support to Cancer Patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 1794-1799.	0.8	17
84	The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. <i>Annals of Oncology</i> , 2009, 20, vii1-vii6.	0.6	94
85	Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. <i>Annals of Oncology</i> , 2009, 20, 1062-1067.	0.6	18
86	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 872-877.	0.8	539
87	Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. <i>Journal of Clinical Oncology</i> , 2009, 27, 3117-3125.	0.8	437
88	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. <i>BMC Cancer</i> , 2009, 9, 303.	1.1	66
89	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 769-75.	1.1	89
90	Cholangiocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 259-270.	2.0	144

#	ARTICLE	IF	CITATIONS
91	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 160-182.	2.0	14
92	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 127-164.	2.0	347
93	Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The "GISCAD-alternating schedule"™ study findings. <i>European Journal of Cancer</i> , 2009, 45, 65-73.	1.3	48
94	Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-III AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database. <i>European Journal of Cancer</i> , 2009, 45, 2537-2545.	1.3	82
95	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. <i>Lung Cancer</i> , 2009, 64, 199-206.	0.9	20
96	Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. <i>Lancet Oncology</i> , The, 2009, 10, 943-949.	5.1	538
97	Effects of Transdermal Buprenorphine on Patients-reported Outcomes in Cancer Patients. <i>Clinical Journal of Pain</i> , 2009, 25, 671-682.	0.8	8
98	Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey. <i>Supportive Care in Cancer</i> , 2008, 16, 1203-1211.	1.0	30
99	A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF- $\kappa$ B activation. <i>British Journal of Cancer</i> , 2008, 98, 71-76.	2.9	41
100	Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. <i>BMC Cancer</i> , 2008, 8, 82.	1.1	377
101	Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. <i>European Urology</i> , 2008, 54, 1089-1096.	0.9	121
102	Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukes' C Colon Cancer. <i>Clinical Drug Investigation</i> , 2008, 28, 645-655.	1.1	28
103	Raltitrexed (Tomudex®) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). <i>European Journal of Cancer</i> , 2008, 44, 2204-2211.	1.3	38
104	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. <i>Lancet Oncology</i> , The, 2008, 9, 39-44.	5.1	130
105	The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. <i>Annals of Oncology</i> , 2008, 19, vi1-vi8.	0.6	59
106	Impact of recent legislative bills regarding clinical research on Italian ethics committee activity. <i>Journal of Medical Ethics</i> , 2008, 34, 747-750.	1.0	11
107	Venous Thromboembolism and Pancreatic Cancer: Incidence, Pathogenesis and Clinical Implications. <i>Onkologie</i> , 2008, 31, 129-135.	1.1	3
108	Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 4906-4911.	0.8	530

#	ARTICLE	IF	CITATIONS
109	Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa. <i>Journal of Clinical Oncology</i> , 2008, 26, 1619-1625.	0.8	161
110	Perioperative or postoperative therapy for resectable gastric cancer?. <i>Annals of Oncology</i> , 2008, 19, v99-v102.	0.6	4
111	Axillary recurrence in sentinel lymph node-negative breast cancer patients. <i>Annals of Oncology</i> , 2008, 19, 1842-1846.	0.6	23
112	Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC. <i>Journal of the National Cancer Institute</i> , 2008, 100, 388-398.	3.0	123
113	Predicting response of molecular targeted therapies: a still possible challenge?. <i>Annals of Oncology</i> , 2008, 19, 829-830.	0.6	3
114	Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program. <i>Journal of Thoracic Oncology</i> , 2008, 3, 764-771.	0.5	59
115	Erlotinib in Pancreatic Cancer Patients: Do We Need More Information From the NCIC CTG Trial?. <i>Journal of Clinical Oncology</i> , 2007, 25, 4320-4321.	0.8	3
116	Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 887-897.	1.1	9
117	What is the real benefit of adjuvant chemotherapy in the Adjuvant Navelbine International Trialist Association trial?. <i>Annals of Oncology</i> , 2007, 18, 404.	0.6	0
118	Response: Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1346-1347.	3.0	1
119	Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials. <i>Journal of the National Cancer Institute</i> , 2007, 99, 998-1003.	3.0	291
120	Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. <i>Annals of Oncology</i> , 2007, 18, 1660-1665.	0.6	116
121	Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. <i>Annals of Oncology</i> , 2007, 18, 1652-1659.	0.6	105
122	Agreement between oncology guidelines and clinical practice in Italy: the "right" program. A project of the Italian Association of Medical Oncology (AIOM). <i>Annals of Oncology</i> , 2007, 18, vi179-vi184.	0.6	11
123	Nuclear Factor-κB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3930-3935.	0.8	121
124	Breast cancer follow-up: just a burden, or much more?. <i>Annals of Oncology</i> , 2007, 18, 1431-1432.	0.6	2
125	Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 601-607.	3.0	96
126	End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4569-4574.	0.8	220

#	ARTICLE	IF	CITATIONS
127	Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies. <i>Journal of Clinical Oncology</i> , 2007, 25, 326-331.	0.8	485
128	Reversible palpebral ptosis following oxaliplatin infusion. <i>Digestive and Liver Disease</i> , 2007, 39, 1041.	0.4	5
129	Comprehensive Geriatric Assessment in Elderly Cancer Patients: An Experience in an Outpatient Population. <i>Tumori</i> , 2007, 93, 23-25.	0.6	16
130	The role of adjuvant chemotherapy in colon cancer. <i>Surgical Oncology</i> , 2007, 16, 93-96.	0.8	13
131	Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study. <i>World Journal of Gastroenterology</i> , 2007, 13, 6553.	1.4	4
132	Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 7.	1.0	23
133	Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer. <i>Tumori</i> , 2006, 92, 384-388.	0.6	17
134	Oncologists' opinions about research ethics committees in Italy: an update, 2004. <i>European Journal of Cancer Prevention</i> , 2006, 15, 91-94.	0.6	5
135	Edmonton symptom assessment scale: Italian validation in two palliative care settings. <i>Supportive Care in Cancer</i> , 2006, 14, 30-37.	1.0	177
136	Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM). <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 194-204.	2.0	119
137	Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab. <i>Targeted Oncology</i> , 2006, 1, 2-12.	1.7	2
138	Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study. <i>Oncology</i> , 2006, 71, 374-381.	0.9	14
139	Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy. <i>Annals of Oncology</i> , 2006, 17, 1466-1467.	0.6	8
140	Challenges in the treatment of gastrointestinal tumours. <i>Annals of Oncology</i> , 2006, 17, v137-v141.	0.6	2
141	Are Dose-Finding Studies Still Necessary When Targeted Therapy Is Associated With Chemotherapy?. <i>Journal of Clinical Oncology</i> , 2006, 24, 4668-4669.	0.8	0
142	Introduction. <i>Annals of Oncology</i> , 2006, 17, v5-v6.	0.6	5
143	New strategies in colon cancer adjuvant therapy. <i>Annals of Oncology</i> , 2006, 17, vii51-vii54.	0.6	5
144	Optimizing use of opiates in the management of cancer pain. <i>Therapeutics and Clinical Risk Management</i> , 2006, 2, 447-453.	0.9	19

#	ARTICLE	IF	CITATIONS
145	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 54, 209-241.	2.0	73
146	Midazolam for Long-Term Treatment of Intractable Hiccup. <i>Journal of Pain and Symptom Management</i> , 2005, 29, 222-223.	0.6	21
147	A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. <i>Cancer</i> , 2005, 103, 772-779.	2.0	10
148	Cost of Insurance Policies for Investigator-Initiated Cancer Clinical Trials in Italy. <i>Tumori</i> , 2005, 91, 373-379.	0.6	4
149	Colorectal cancer: screening. <i>Annals of Oncology</i> , 2005, 16, ii127-ii132.	0.6	25
150	Tailoring a tailored treatment: the importance of fine-tuning on the patient. <i>Annals of Oncology</i> , 2005, 16, 683-685.	0.6	0
151	The development of clinical research in CRC. <i>Annals of Oncology</i> , 2005, 16, iv37-iv43.	0.6	14
152	The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients. <i>Oncology</i> , 2005, 68, 212-216.	0.9	4
153	Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 3509-3516.	0.8	878
154	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 8664-8670.	0.8	607
155	Targeted therapy in colorectal cancer: do we know enough?. <i>Digestive and Liver Disease</i> , 2005, 38, 71-7.	0.4	7
156	Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. <i>Journal of Clinical Oncology</i> , 2004, 22, 1797-1806.	0.8	913
157	Insurance for independent cancer trials. <i>Annals of Oncology</i> , 2004, 15, 1722-1723.	0.6	3
158	High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , 2004, 90, 1521-1525.	2.9	58
159	Randomized Trial of Intraportal and/or Systemic Adjuvant Chemotherapy in Patients With Colon Carcinoma. <i>Journal of the National Cancer Institute</i> , 2004, 96, 750-758.	3.0	24
160	Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. <i>British Journal of Cancer</i> , 2004, 91, 1428-1433.	2.9	1
161	Adjuvant treatment of colorectal cancer. <i>Surgical Oncology</i> , 2004, 13, 63-73.	0.8	14
162	Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. <i>Supportive Care in Cancer</i> , 2004, 12, 446-453.	1.0	34

#	ARTICLE	IF	CITATIONS
163	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 51, 145-170.	2.0	29
164	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 51, 121-143.	2.0	8
165	The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 52, 73-80.	2.0	4
166	Colorectal cancer in 2003: state of the art and new developments. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 1-2.	2.2	0
167	Elderly colorectal cancer patients are under treated. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 8-13.	2.2	4
168	Population-based sentinel lymph node biopsy in early invasive breast cancer. <i>European Journal of Surgical Oncology</i> , 2004, 30, 618-623.	0.5	2
169	Adjuvant therapy for stage II colon cancer: an elephant in the living room?. <i>Annals of Oncology</i> , 2004, 15, 1310-1318.	0.6	58
170	Pain and its treatment in hospitalized patients with metastatic cancer. <i>Supportive Care in Cancer</i> , 2003, 11, 587-592.	1.0	36
171	Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. <i>Journal of Translational Medicine</i> , 2003, 1, 13.	1.8	10
172	Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. <i>European Journal of Cancer</i> , 2003, 39, 1577-1585.	1.3	56
173	Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. <i>European Journal of Cancer</i> , 2003, 39, 1948-1956.	1.3	87
174	A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. <i>British Journal of Cancer</i> , 2003, 89, 1428-1432.	2.9	22
175	Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. <i>Annals of Oncology</i> , 2003, 14, 1570-1577.	0.6	410
176	Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. <i>Annals of Oncology</i> , 2003, 14, 843-848.	0.6	27
177	Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Annals of Oncology</i> , 2003, 14, 205-208.	0.6	27
178	Chemotherapy in Small Bowel Adenocarcinoma Associated with Celiac Disease: A Report of Three Cases. <i>Tumori</i> , 2003, 89, 193-195.	0.6	7
179	Gastrointestinal Stromal Tumors: Should They Be Treated with the Same Systemic Chemotherapy as Other Soft Tissue Sarcomas?. <i>Oncology</i> , 2003, 64, 186-188.	0.9	15
180	Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: A low cost effective regimen. <i>British Journal of Cancer</i> , 2002, 86, 213-217.	2.9	13

#	ARTICLE	IF	CITATIONS
181	Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 1600-1607.	0.8	80
182	Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 3478-3483.	0.8	331
183	Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). <i>Annals of Oncology</i> , 2002, 13, 716-720.	0.6	45
184	Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. <i>Annals of Oncology</i> , 2002, 13, 1438-1446.	0.6	196
185	Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 <i>Cancer</i> , 2002, 38, 1429-1436.	1.3	50
186	Individual Tailored Chemotherapy. <i>Tumori</i> , 2002, 1, S25-S27.	0.6	0
187	Is There an Advantage for Oral Therapy in Elderly? <i>Uft. Tumori</i> , 2002, 88, S71-S72.	0.6	0
188	Medical Treatment of Colorectal Cancer in Elderly (>70 Years): Giscad Experience and Future Perspectives. <i>Tumori</i> , 2002, 88, S109-S112.	0.6	2
189	Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 1600-1607.	0.8	111
190	â€œMisuraâ€•Project: A Retrospective Survey on the Use of 5fluorouracil in the Treatment of Colorectal Cancer in 24 Italian Clinical Centers. <i>Tumori</i> , 2002, 88, 104-109.	0.6	1
191	New drugs and combinations in the palliative treatment of colon and rectal cancer. <i>European Journal of Surgical Oncology</i> , 2001, 27, 595-600.	0.5	13
192	A Multinational Study to Measure the Value that Patients with Cancer Place on Improved Emesis Control Following Cisplatin Chemotherapy. <i>Pharmacoeconomics</i> , 2001, 19, 955-967.	1.7	18
193	Pre-operative endocrine therapy for postmenopausal women: When and why?. <i>Annals of Oncology</i> , 2001, 12, 1505-1506.	0.6	3
194	Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. <i>Annals of Oncology</i> , 2001, 12, 13-22.	0.6	47
195	Idiosyncratic reaction after oxaliplatin infusion. <i>Annals of Oncology</i> , 2001, 12, 132-133.	0.6	48
196	Treatment of Classical Kaposiâ€™s Sarcoma with Gemcitabine. <i>Dermatology</i> , 2001, 202, 119-122.	0.9	32
197	A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. <i>British Journal of Cancer</i> , 2001, 84, 470-474.	2.9	39
198	A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients. <i>New England Journal of Medicine</i> , 2001, 345, 1091-1097.	13.9	931

#	ARTICLE	IF	CITATIONS
199	Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. <i>Annals of Oncology</i> , 2000, 11, 837-843.	0.6	339
200	A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Annals of Oncology</i> , 2000, 11, 1309-1312.	0.6	32
201	The Value of Oxaliplatin in Combination with Continuous infusion $\pm$ Bolus 5-Fluorouracil and Levo-Folinic Acid in Metastatic Colorectal Cancer Progressing after 5FU-Based Chemotherapy: A Giscad (Italian Group for the Study of Digestive Tract) Cancer Phase II Trial. <i>Tumori</i> , 2000, 86, 465-469.	0.6	11
202	Trattamento Adiuvante del Carcinoma del Colon Stato Dell'arte e Prospettive Future. <i>Tumori</i> , 1999, 85, A1-A6.	0.6	0
203	Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , 1999, 79, 491-494.	2.9	7
204	A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , 1999, 80, 1595-1598.	2.9	81
205	A New Palliative Prognostic Score. <i>Journal of Pain and Symptom Management</i> , 1999, 17, 231-239.	0.6	386
206	Successful Validation of the Palliative Prognostic Score in Terminally Ill Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 1999, 17, 240-247.	0.6	365
207	Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy. <i>Lancet, The</i> , 1999, 353, 1310-1314.	6.3	36
208	A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. <i>Annals of Oncology</i> , 1999, 10, 985-987.	0.6	5
209	Which 5-fluorouracil regimen? "the great debate. <i>Anti-Cancer Drugs</i> , 1999, 10, 337-354.	0.7	19
210	Subcutaneous Administration of Interleukin-2 and Interferon-alpha2b in Advanced Renal Cell Carcinoma: Long-Term Results. <i>Cancer Detection and Prevention</i> , 1999, 23, 172-176.	2.1	8
211	GIVIO-SITAC 01. , 1998, 82, 2135-2144.		59
212	Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. <i>Lancet, The</i> , 1998, 351, 1677-1681.	6.3	81
213	Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. <i>Lancet, The</i> , 1998, 352, 1407-1412.	6.3	958
214	Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. <i>Annals of Oncology</i> , 1998, 9, 105-108.	0.6	205
215	Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients. <i>Annals of Oncology</i> , 1998, 9, 365-374.	0.6	84
216	5-FLUOROURACILE E TUMORI DEL COLON-RETTO: IMPIEGO NELLA PRATICA CLINICA E PROGETTO "MISURA". <i>Tumori</i> , 1998, 84, S10-S12.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg. Tumori, 1998, 84, 335-347.	0.6	14
218	Treatment of Colorectal Cancer. Drugs, 1997, 53, 593-607.	4.9	58
219	Should patients with advanced colorectal cancer be treated with chemothreapy?. European Journal of Cancer, 1997, 33, 818-822.	1.3	3
220	Should patients with advanced colorectal cancer be treated with chemotherapy?. European Journal of Cancer, 1997, 33, 815-817.	1.3	7
221	Gastrointestinal Tract Cancer Liaison Office: An attempt to organise clinical research in Europe. European Journal of Cancer, 1997, 33, 1536-1545.	1.3	2
222	High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A "GISCAD"™ phase III study. Annals of Oncology, 1997, 8, 169-174.	0.6	25
223	Response Evaluation as the Key-point in Results Interpretation. Tumori, 1997, 83, 73-76.	0.6	2
224	Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Journal of Pain and Symptom Management, 1997, 13, 1-9.	0.6	100
225	Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. Supportive Care in Cancer, 1997, 5, 314-317.	1.0	29
226	Cisplatin-associated anaemia in patients with solid tumours. Supportive Care in Cancer, 1996, 4, 218-219.	1.0	6
227	Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An italian group for the study of digestive tract cancer (GISCAD) report. Cancer, 1995, 76, 1694-1699.	2.0	48
228	Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. British Journal of Cancer, 1995, 72, 1531-1535.	2.9	25
229	Prognostic factors in resectable gastric cancer: Results of EORTC study no. 40813 on FAM adjuvant chemotherapy. Annals of Surgical Oncology, 1995, 2, 495-501.	0.7	27
230	Oral Etoposide as Second-Line Chemotherapy for Colorectal Cancer: a GISCAD* Study. Journal of Chemotherapy, 1995, 7, 246-248.	0.7	5
231	Mediterranean Kaposi's sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine. Cancer, 1994, 74, 2873-2878.	2.0	53
232	Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-±2b and folinic acid. The "GISCAD"•experience. European Journal of Cancer, 1994, 30, 1611-1616.	1.3	7
233	Phase II trial of 5-fluorouracil and the natural I isomer of folinic acid in the treatment of advanced colorectal carcinoma. European Journal of Cancer, 1994, 30, 338-343.	1.3	23
234	Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: A study by the Italian trials in Medical Oncology Group. Cancer, 1993, 72, 3099-3105.	2.0	121

#	ARTICLE	IF	CITATIONS
235	A Cisplatin- Cyclophosphamide Regimen in Advanced Ovarian Cancer: Reporting 5-Year Results. <i>Oncology</i> , 1993, 50, 92-99.	0.9	2
236	Chemotherapy for patients not benefitting from 5-fluorouracil therapy. <i>Journal of Surgical Oncology</i> , 1991, 48, 161-164.	0.8	0
237	Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 1579-1581.	0.9	22
238	Epirubicin Treatment of Advanced Breast Carcinoma with the Weekly Low-Dose Regimen. <i>Oncology</i> , 1987, 44, 6-12.	0.9	17
239	The meaning of bites on the vectorcardiogram: Study in adriamycin cardiomyopathy. <i>Journal of Electrocardiology</i> , 1982, 15, 265-270.	0.4	9
240	Cardiac Toxicity of 5-Fluorouracil: A Study on 1083 Patients. <i>Tumori</i> , 1982, 68, 505-510.	0.6	250
241	Antitumor chemotherapy after fluorouracil angina. <i>Journal of Cancer Research and Clinical Oncology</i> , 1982, 104, 321-322.	1.2	12
242	Cardiac Toxicity from Antitumor Therapy. <i>Oncology</i> , 1980, 37, 51-58.	0.9	21
243	CARCINOEMBRYONIC ANTIGEN REVISITED. <i>Lancet</i> , The, 1977, 309, 756.	6.3	0